GUYER DAVID R 4
4 · EyePoint Pharmaceuticals, Inc. · Filed Jul 16, 2024
Insider Transaction Report
Form 4
GUYER DAVID R
Director
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-07-12−3,250→ 3,250 totalExercise: $3.50From: 2024-02-23Exp: 2033-06-19→ Common Stock (3,250 underlying) - Sale
Common Stock
2024-07-12$10.06/sh−11,625$116,995→ 1,850 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-07-12−6,525→ 6,525 totalExercise: $3.26From: 2024-01-06Exp: 2033-06-19→ Common Stock (6,525 underlying) - Exercise/Conversion
Common Stock
2024-07-12$3.26/sh+6,525$21,272→ 13,475 total - Exercise/Conversion
Common Stock
2024-07-12$3.50/sh+3,250$11,375→ 6,950 total
Footnotes (1)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.125. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.